Skip to Content

Conjugated estrogens / medroxyprogesterone Pregnancy and Breastfeeding Warnings

Conjugated estrogens / medroxyprogesterone is also known as: Premphase, Premphase 14/14, Prempro

Conjugated estrogens / medroxyprogesterone Pregnancy Warnings

Specific categories of malformations associated with conjugated estrogens use include cardiovascular defects, hypospadias, eye and ear malformations, and Down syndrome. In the Collaborative Perinatal Project involving 50,282 pregnancies, 866 first trimester exposures to progestational agents were documented. Of these, there were 130 exposures to medroxyprogesterone. The incidence of cardiovascular defects was significantly increased, with a standardized relative risk of 1.8. While not statistically significant, data also suggested an increased risk of hypospadias among offspring of women treated with progestational agents in the first trimester. In the Michigan Medicaid Birth Defects Study involving 229,101 pregnancies from 1985 to 1992, there were 327 first trimester exposures to medroxyprogesterone (written communication, Franz Rosa, MD, Food and Drug Administration, 1994). Overall, 15 cases of birth defects were observed (13 cases expected). Seven cases of cardiovascular defects occurred compared with 3 cases expected, representing a significant increase in the incidence of cardiovascular defects. Of interest, in all seven cases, the indication for maternal treatment with medroxyprogesterone was amenorrhea and not threatened spontaneous abortion. No cases of hypospadias occurred. Other studies have failed to find an association between first trimester use of progestational agents and congenital anomalies, including cardiovascular and genitourinary defects. In addition, follow-up studies have concluded that the use of medroxyprogesterone during pregnancy does not affect the long-term growth and development of children. There are data which suggest an increase in the frequency of low birth weight among infants of accidental pregnancies during contraception with intramuscular medroxyprogesterone.

Conjugated estrogens-medroxyprogesterone has not been formally assigned to a pregnancy category by the FDA. Conjugated estrogens and medroxyprogesterone have been assigned to pregnancy Risk Factor X by Briggs et al. Animal studies have not been reported. There are no controlled data in human pregnancy. Conjugated estrogens-medroxyprogesterone is considered contraindicated during pregnancy.

See references

Conjugated estrogens / medroxyprogesterone Breastfeeding Warnings

There are no data on the excretion of conjugated estrogens into human milk. However, a decrease in quality and quantity of milk is associated with the administration of estrogen to nursing women. The American Academy of Pediatrics considers estradiol, another estrogenic agent, to be compatible with breast-feeding. Medroxyprogesterone is excreted into breast milk. Lactation does not appear to be adversely affected by contraceptive use of medroxyprogesterone. The American Academy of Pediatrics considers the use of medroxyprogesterone to be compatible with breast-feeding. The manufacturer recommends that caution be used when administering conjugated estrogens-medroxyprogesterone to nursing women.

The excretion of medroxyprogesterone into breast milk was evaluated in 10 women who received medroxyprogesterone acetate 150 mg intramuscularly for contraception. Mean medroxyprogesterone milk concentrations ranged from approximately 8 ng/mL at one week to approximately 0.5 ng/mL at 12 weeks after the injection. The milk to maternal serum concentration ratio ranged from 0.12 to 2.60 (mean 0.88). Contraceptive use of medroxyprogesterone does not adversely affect the content or volume of breast milk. In addition, progestin during lactation may promote longer duration of lactation. Long-term follow-up studies of up to eight years duration have failed to document adverse development effects due to exposure to medroxyprogesterone in breast milk.

See references

References for pregnancy information

  1. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. Jaffe B, Harlap S, Baras M, Gordon L, Lieblich A, Magidor S, Sanchez M "Long-term effects of MPA on human progeny: intellectual development." Contraception 37 (1988): 607-19
  3. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  4. Katz Z, Lancet M, Skornik J, Chemke J, Mogilner BM, Klinberg M "Teratogenicity of progestogens given during the first trimester of pregnancy." Obstet Gynecol 65 (1985): 775-80
  5. Resseguie LJ, Hick JF, Bruen JA, Noller KL, O'Fallon WM, Kurland LT "Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974." Fertil Steril 43 (1985): 514-9
  6. Jaffe B, Shye D, Harlap S, Baras M, Lieblich A "Aggression, physical activity levels and sex role identity in teenagers exposed in utero to MPA." Contraception 40 (1989): 351-63
  7. Pardthaisong T, Yenchit C, Gray R "The long-term growth and development of children exposed to Depo- Provera during pregnancy or lactation." Contraception 45 (1992): 313-24
  8. Pardthaisong T, Gray RH "In utero exposure to steroid contraceptives and outcome of pregnancy" Am J Epidemiol 134 (1991): 795-803
  9. Gray RH, Pardthaisong T "In utero exposure to steroid contraceptives and survival during infancy" Am J Epidemiol 134 (1991): 804-11
  10. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  11. Yovich JL, Turner SR, Draper R "Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects." Teratology 38 (1988): 135-44
  12. Schwallie PC "The effect of depot-medroxyprogesterone acetate on the fetus and nursing infant: a review." Contraception 23 (1981): 375-86
  13. Heinonen O, Slone D, Shapiro S; Kaufman DW ed. "Birth Defects and Drugs in Pregnancy." Littleton, MA: Publishing Sciences Group, Inc. (1977): 297
  14. Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994): 189-201

References for breastfeeding information

  1. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. Dahlberg K "Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user." Int J Gynaecol Obstet 20 (1982): 43-8
  3. Hefnawi F, Fawzi G, Badraoui MH "Effect of some progestational steroids on lactation in Egyptian women. I. Milk yield during the first year of lactation." J Biosoc Sci 8 (1976): 45-8
  4. Jimenez J, Ochoa M, Soler MP, Portales P "Long-term follow-up of children breast-fed by mothers receiving depot- medroxyprogesterone acetate." Contraception 30 (1984): 523-33
  5. Abdel Kader MM, Abdel Aziz MT, Bahgat R, Hefnawi F, Fawzi G, Badraoui MH "Effect of some progestational steroids on lactation in Egyptian women. II. Chemical composition of milk during the first year of lactation." J Biosoc Sci 8 (1976): 49-51
  6. Committee on Drugs, 1992 to 1993 "The transfer of drugs and other chemicals into human milk." Pediatrics 93 (1994): 137-50
  7. Shaaban MM "Contraception with progestogens and progesterone during lactation." J Steroid Biochem Mol Biol 40 (1991): 705-10
  8. Koetsawang S, Nukulkarn P, Fotherby K, Shrimanker K, Mangalam M, Towobola K "Transfer of contraceptive steroids in milk of women using long-acting gestagens." Contraception 25 (1982): 321-31
  9. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  10. Schwallie PC "The effect of depot-medroxyprogesterone acetate on the fetus and nursing infant: a review." Contraception 23 (1981): 375-86

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.